U.S. markets open in 4 hours 8 minutes

Moderna, Inc. (MRNA)

NasdaqGS - NasdaqGS Precio en tiempo real. Divisa en USD.
Añadir a la lista de seguimiento
98.17-1.82 (-1.82%)
Al cierre: 04:00PM EDT
98.20 +0.03 (+0.03%)
Antes de la apertura del mercado: 04:56AM EDT

Moderna, Inc.

200 Technology Square
Cambridge, MA 02139
United States
617 714 6500
https://www.modernatx.com

Sector(es)Healthcare
IndustriaBiotechnology
Empleados a tiempo completo3,900

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Mr. Stephane BancelCEO & Director4.97M392.58M1973
Dr. Stephen Hoge M.D.Pres2.41M56.52M1976
Mr. James M. MockChief Financial Officer1.49MN/D1977
Ms. Arpa GarayChief Commercial Officer2.67MN/D1979
Dr. Jerh Collins Ph.D.Chief Technical Operations & Quality OfficerN/DN/D1966
Dr. Melissa J. Moore Ph.D.Chief Scientific Officer & Member of Scientific Advisory BoardN/DN/DN/D
Mr. Brad MillerChief Information OfficerN/DN/D1973
Ms. Lavina Talukdar CFASr. VP & Head of Investor RelationsN/DN/DN/D
Ms. Shannon Thyme KlingerChief Legal Officer & Corp. Sec.N/DN/D1971
Colleen HusseySr. Director of Corp. CommunicationsN/DN/DN/D
Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Gestión corporativa

La calificación ISS Governance QuickScore de Moderna, Inc. a partir del 1 de septiembre de 2023 es 10. Las puntuaciones principales son Auditoría: 8; Junta: 9; Derechos del accionista: 10; Compensación: 9.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.